Next week, our Scientific & Regulatory Affairs Associate Director Christopher Mann will be participating in the Invasive Therapies Meeting organised by European Huntington’s Disease Network (EHDN) Invasive Therapies Working Group, in collaboration with SCHD (Stem cells for HD).
This working group meeting will take place on 26-27 April in Barcelona and the main goal is to share experiences and best practices for therapies that require direct delivery into the brain.
Asphalion is already a regulatory partner in several projects for advanced and innovative therapies.
We are commitment to support advanced therapies development and we believe these therapies will bring important health benefits.
For more information contact us: email@example.com